This week, we have a conversation with Revalesio president Greg Archambeau about tackling strokes, and other conditions, with a novel method.

Revalesio

While the pharmaceutical industry often focuses on complex chemical compounds, Revalesio is pioneering a novel drug class rooted in a surprising field: fluid physics.

Revalesio is also focusing on stroke, a condition in need of new therapies.

Revalesio’s breakthrough therapy, RNS60, is unlike traditional treatments. It uses a proprietary process to create an oxygen-supersaturated saline that harnesses physical forces to fundamentally improve cellular health. By boosting mitochondrial biogenesis and ATP production, the therapy addresses the core of cellular decline.

Revalesio  ...